SFI is mainly used for the adjuvant treatment of lung cancer and gastric cancer as a large infusion solution widely used in clinical application, can improve fatigue-like behavior in cancer-related fatigue mouse models by inhibiting the production of pro-inflammatory cytokines produced by peripheral immune cells, inhibit the dysfunction of failing T cells, and improve the body’s anti-tumor immunity by targeting targets such as PD-L1, TIM3 and FOXP3 (Zhu et al. 2019). The gene discussed is HAVCR2; the disease is lung cancer.